Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 13/20 | 0.49 |
| ▸ | CTSS | P25774 | 11/20 | 0.49 |
| ▸ | CTSK | P43235 | 10/20 | 0.49 |
| ▸ | CTSB | P07858 | 7/20 | 0.49 |
| ▸ | CTSC | P53634 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 5/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7075165 | 0.87 | CTSC (0.49) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL7075206 | 0.87 | CTSL (0.50) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL7076292 | 0.84 | CTSC (0.48) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL6108566 | 0.80 | CTSS (0.59) | CTSLCTSSCTSKCTSBCTSV | |
| SCHEMBL5372395 | 0.78 | CTSC (0.47) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL5364821 | 0.77 | CTSL (0.46) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL5368636 | 0.75 | CA12 (0.46) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL5360545 | 0.74 | CTSS (0.50) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL7074908 | 0.73 | CTSS (0.46) | CTSLCTSSCTSKCTSBCTSC | |
| SCHEMBL7029373 | 0.72 | PNMT (0.58) | CTSLCTSSCTSKCTSBHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CTSL 9/4885CTSS 1/4885CTSK 2/4885 |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CTSL 9/4885CTSS 1/4885CTSK 2/4885 |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CTSL 9/4885CTSS 1/4885CTSK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.